MedMira Reports Fiscal First Quarter 2016 Financial Results
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwired) -- 12/14/15 -- MedMira Inc. (MedMira) (TSX VENTURE: MIR), reported today on its financial results for the three month period ending October 31, 2015. The Company recorded a 210% increase in revenue and a 202% increase in gross profit during the first quarter, compared to the same period last year.
"MedMira has carried the positive financial momentum we created in FY2015 forward into first quarter FY2016 with continued sales in high margin markets and increased gross profit," said Markus Meile, Chief Financial Officer, MedMira Inc. "While expenses increased slightly this quarter due to additional product development and commercialization activities, we are excited about the launch of Reveal(r) G4 in the U.S. market and the slate of additional new product concepts in development for 2016."
Financial Highlights
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology™. The Company''s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company''s tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. MedMira''s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in Atlanta, Georgia, United States. For more information visit . Follow us on and .
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company''s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
MedMira Inc.
Andrea Young
Corporate Communications
902-450-1588
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.12.2015 - 16:30 Uhr
Sprache: Deutsch
News-ID 1404290
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MedMira Reports Fiscal First Quarter 2016 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
MedMira Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
